Expert Insights on Dedifferentiated Liposarcoma: Diagnosis & Emerging Therapies скачать в хорошем качестве

Expert Insights on Dedifferentiated Liposarcoma: Diagnosis & Emerging Therapies

Claim your credit here: https://bit.ly/3D3tF7H Explore the complexities of diagnosing and managing dedifferentiated liposarcoma (DDLPS) in this expert-led podcast featuring Dr. Richard F. Riedel of Duke University and Dr. Candace L. Haddox of Dana-Farber Cancer Institute. STATEMENT OF NEED Dedifferentiated liposarcoma (DDLPS) is an aggressive subtype of soft tissue sarcoma. Detection of MDM2 and/or CDK4 amplification distinguishes DDLPS from other types of undifferentiated sarcomas. Diagnosis of DDLPS remains challenging due to its complex karyotypes, quantitative genomic profiles, and pleomorphic pathological features (Nishio et al, 2021; Shen et al, 2022). Currently, surgical resection with or without radiation is the mainstay of treatment for localized disease, and anthracycline-based therapy is a standard first-line treatment for advanced disease. Numerous novel therapies are currently under investigation, including CDK4/6 inhibitors, MDM2-p53 pathway inhibitors, and immunotherapies, with the potential to transform the treatment landscape for DDLPS (Nishio et al, 2021). Due to the complex management of DDLPS, collaboration of the multidisciplinary health care team, including medical oncologists, surgical oncologists, radiation oncologists, and pathologists, is crucial. This Dedifferentiated Liposarcoma Task Force podcast will provide a consensus opinion on the optimal diagnosis, treatment, and management of this disease. It features perspectives from Task Force co-chairs Richard F. Riedel, MD, Associate Professor in the Division of Medical Oncology at Duke University Medical Center, and Candace L. Haddox, MD, Physician at Dana-Farber Cancer Institute and Instructor in Medicine at Harvard Medical School. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to Summarize the key clinical, histopathologic, and genomic characteristics that make dedifferentiated liposarcoma unique from other soft tissue sarcoma subtypes Assess the benefits and limitations of current molecular testing methodologies for the characterization of soft tissue sarcomas Appreciate the role of a multimodality approach in the management of localized dedifferentiated liposarcoma, as well as the current systemic therapy landscape for patients with advanced disease Evaluate potential emerging therapies, including MDM2-p53 pathway inhibitors, CDK4/6 inhibitors, and immunotherapeutic approaches, for the treatment of dedifferentiated liposarcoma DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Richard F. Riedel, MD, discloses that he has received grants/research support from Aadi Bioscience, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, InhibRx, NanoCarrier, Oncternal, PTC Therapeutics, SARC, SpringWorks, TRACON, and Trillium; and that he has served as a consultant or on an advisory board/panel for Aadi Bioscience, Adaptimmune, Bayer, Blueprint, Boehringer Inhelheim, Daiichi-Sankyo, Decipheral, GlaxoSmithKline, NanoCarrier, and SpringWorks. Candace L. Haddox, MD, discloses that she has served as a consultant or on an advisory/board panel for Aadi Bioscience; and that she has received grants/research support from Aadi Bioscience, EMD Serono, Cogent, HiFiBio, Roche, and Tango Therapeutics. #DDLPS #Liposarcoma #CMEPodcast #OncologyEducation #MDM2Amplification #CDK4Inhibitors #Immunotherapy #CancerCare #SoftTissueSarcoma